ライフサイエンスコーパス: H1N1 vaccine

1 and no cases following live attenuated 2009 H1N1 vaccine.

2 cords on more than 2.6 million doses of 2009 H1N1 vaccine.

3 en <10 years of age required 2 doses of 2009 H1N1 vaccine.

4 accine than against the homotypic seasonal A(H1N1) vaccine.

5 l, 39 726 infants were prenatally exposed to H1N1 vaccine (13 845 during the first trimester) and 29

6 Subjects received the H1N1 vaccine (15-microg dose; Novartis), and antibody ti

7 receive 2 doses of 15 mug or 30 mug HA 2009 H1N1 vaccine 21 days apart.

8 few studies examine the immune responses to H1N1 vaccine among children and adults of various body m

9 e no significant differences in responses to H1N1 vaccine among children or adults of various BMI fol

10 Generally, 1 dose of 2009 H1N1 vaccine and 1 dose of TIV, regardless of sequence o

11 o those against the heterovariant seasonal A(H1N1) vaccine and were similar between young and elderly

12 monovalent 2009 H1N1 influenza vaccine (2009 H1N1 vaccine) and seasonal trivalent inactivated influen

13 re immunized with commercial monovalent 2009 H1N1 vaccine, and antigen-specific antibody responses an

14 These changes allowed direct delivery of an H1N1 vaccine antigen and a diclofenac nanotherapeutic in

15 eared in April of 2009, development of novel H1N1 vaccines became a public health priority.

16 When pandemic H1N1 vaccines become available, the safety and efficacy

17 We administered 1 or 2 doses of pandemic H1N1 vaccine (CA/7 ca), a seasonal trivalent inactivated

18 tantly, vaccination of pigs with a ty/04 att-H1N1 vaccine candidate resulted in sterilizing immunity

19 In vivo characterization of two H1N1 vaccine candidates generated using the ty/04 att ba

20 responses and protectiveness induced by 2009 H1N1 vaccine could be extremely compromised in diet-indu

21 /34, A/Texas/36/91, or A/New Caledonia/20/99 H1N1 vaccines displayed partial protection from lethal c

22 ing exposed and unexposed to the influenza A(H1N1) vaccine during pregnancy were matched 1:4 on prope

23 Median monovalent pandemic H1N1 vaccine effectiveness in five observational studies

24 A case-control evaluation of 2009 H1N1 vaccine effectiveness was conducted in schools in C

25 rate that vaccination with the 2009 pandemic H1N1 vaccine elicits 1918 virus cross-protective antibod

26 CR) serum antibodies that recognize both the H1N1 (vaccine-H1) and H3N2 (vaccine-H3) components of an

27 potential adverse effects of the pandemic A(H1N1) vaccine have supported that influenza A(H1N1) vacc

28 lammatory occlusive retinal vasculitis, post-H1N1 vaccine, hypertensive retinopathy, migraine disorde

29 Increasing the HA dose of the 2009 H1N1 vaccine improves the vaccine's immunogenicity in HI

30 d 1 dose of seasonal TIV and 2 doses of 2009 H1N1 vaccine in 1 of 4 combinations.

31 led, observer-blind clinical trial of a 2009 H1N1 vaccine in 1313 young (age, 18-64 years) and older

32 the long-term antibody response to the 2009-H1N1 vaccine in solid organ transplant recipients (SOTR)

33 that of 2 doses of nonadjuvanted influenza A(H1N1) vaccine in children 6 months to <10 years of age i

34 ratio following receipt of inactivated 2009 H1N1 vaccine (incidence rate ratio = 2.50, 95% confidenc

35 le 7.5-mug dose of a monovalent unadjuvanted H1N1 vaccine induced protective HI antibody levels in ad

36 The novel association of novel 2009 H1N1 vaccine-induced Ab responses with IL-21/IL-21R upre

37 mained whether the inactivated 2009 pandemic H1N1 vaccine, like the infection, could also induce thes

38 estern state reported receiving the pandemic H1N1 vaccine, physicians and nurses differed significant

39 ng for a diagnosis of asthma, 1 dose of 2009 H1N1 vaccine provided 69% protection (95% confidence int

40 1 or 2 doses of AS03-adjuvanted influenza A(H1N1) vaccine relative to that of 2 doses of nonadjuvant

41 and cellular phenotypes play in influenza A(H1N1) vaccine responsiveness in HIV-infected subjects re

42 Three doses of heterologous monovalent H1N1 vaccine result in seroprotective neutralizing antib

43 ntal challenge with 107 TCID50 of attenuated H1N1 (vaccine strain) by intranasal spray.

44 rization motifs and NA domains from a recent H1N1 vaccine strain and compared for enzymatic propertie

45 The lower immunologic response to the H1N1 vaccine strain compared with the other strains was

46 cine (fluvirin: 18 mug of haemagglutinin per H1N1 vaccine strain, 17 mug of haemagglutinin per H3N2 v

47 -type 3c2.A and 3c2.A2 H3N2 viruses, and the H1N1 vaccine strain.

48 No child shed A/H1N1 vaccine strain.

49 similar to that of the A/New Caledonia/20/99(H1N1) vaccine strain both antigenically and genetically,

50 ponses against the 2009 pandemic influenza A(H1N1) vaccine strain were significantly enhanced, compar

51 ponses against the 2009 pandemic influenza A(H1N1) vaccine strain.

52 th Ab-secreting cells elicited by historical H1N1 vaccine strains.

53 ranasal immunization with PS-GAMP-adjuvanted H1N1 vaccine, strong cross-protection was elicited again

54 e response to a single dose of pandemic 2009 H1N1 vaccine suggests that a large segment of the popula

55 nd vaccination with Pandemrix, an adjuvanted H1N1 vaccine that was used in Europe.

56 s apart of nonadjuvanted A/California/7/2009(H1N1) vaccine (the NAd2 group).

57 controlled trial of a monovalent influenza A H1N1 vaccine to establish the safety and immunogenicity

58 upport the safety profile of the influenza A(H1N1) vaccine used in pregnancy.

59 In Quebec, the 2009 influenza A(H1N1) vaccine was associated with a small but significan

60 The immune responses to 2009 H1N1 vaccine were adequate regardless of the sequence of

61 Two doses of 2009 H1N1 vaccine were required to achieve a protective immun

62 ol studies demonstrated that monovalent 2009 H1N1 vaccines were effective in preventing infection wit